WINDTREE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.93 USD | -4.15% |
|
-19.38% | -69.63% |
| Apr. 16 | Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the AEROSURF Phase II...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Companyâs portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.1
USD
Average target price
18
USD
Spread / Average Target
+339.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.63% | 2.09M | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- WINT Stock
- News Windtree Therapeutics, Inc.
- Transcript : Windtree Therapeutics, Inc. - Special Call